Remicade (infliximab) / Merck (MSD), Tanabe Pharma, J&J - LARVOL DELTA

Cardiovascular Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Case Reports. (PubMed, Cancer Rep (Hoboken)) - "Given the heterogeneity of data, analysis of aggregated data from central repositories like Side Effect Registry Immuno-Oncology (SERIO) would be invaluable."

Adverse events • Checkpoint inhibition • Clinical • Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Oncology

Majocchi's granuloma of the scalp caused by Trichophyton tonsurans in an immunosuppressed adolescent with Crohn's disease: a case report. (PubMed, Front Pediatr) - "A 16-year-old boy with Crohn's disease treated with infliximab and azathioprine developed a painful inflammatory occipital scalp lesion with colliquation, pustulation, and regional lymphadenopathy shortly after a haircut-related injury...The patient improved after switching to itraconazole 200 mg twice daily, combined with repeated surgical debridement, topical antifungal treatment, and temporary interruption of immunosuppression...This case highlights the need for early microbiological and histopathological assessment of severe scalp lesions in immunosuppressed patients, especially after skin-barrier disruption. It also raises awareness of possible dermatophyte transmission related to hairdressing and of a lack of clinical response to terbinafine in dermatophyte infections."

Journal • Crohn's disease • Dermatology • Gastroenterology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pain

Biologic Therapy in Refractory Non-Infectious Uveitis: An Analysis of 60 Cases at a Tertiary Eye Care Centre from South India. (PubMed, Ocul Immunol Inflamm) - "Adalimumab was the most frequently used biologic agent (88.3%) followed by Infliximab (5%), golimumab (3.3%) and tocilizumab (3.3%). Biologic therapy is an effective and safe therapy for refractory non-infectious uveitis across all age-groups and etiologies. Early escalation to biologics may help arrest long-term cumulative inflammatory damage and preserve visual function by sustained inflammatory control."

Journal • Idiopathic Arthritis • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics • Rheumatology • Uveitis

Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). (PubMed, BMJ Open) - P2 | "The findings will be disseminated through peer reviewed publication, national and international conferences and meetings. NCT03684278."

Clinical protocol • Head-to-Head • Journal • P2 data • Infectious Disease • Inflammation • Oncology • Pain • Pancreatitis • CRP

Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206. (PubMed, Front Immunol) - "Our results suggest that internalization of IFX oligomeric aggregates via the mannose receptor pathway significantly contributes to enhanced IFX uptake by DCs and increased routing into the degradative pathway for processing into peptides. Increased presentation of immunogenic peptides may contribute to the augmentation of T-cell recruitment with aggregates compared to the native form. ."

Journal • MRC1

Septic arthritis mimic unmasked: inflammatory bowel disease-associated arthritis in a patient with a learning disability. (PubMed, BMJ Case Rep) - "Colonoscopy and biopsy findings were compatible with Crohn's disease. Antibiotics were stopped and prednisone plus methotrexate, then infliximab, led to clinical and laboratory improvement with no active bowel inflammation on follow-up MR enterography."

Journal • Cognitive Disorders • Crohn's disease • Dermatology • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Rheumatology

Development and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes. (PubMed, J Pharm Biomed Anal) - "Four IC models with known epitopes (tumor necrosis factor alpha-adalimumab, tumor necrosis factor alpha-infliximab, human epidermal growth factor receptor 2-pertuzumab, and human epidermal growth factor receptor 2-trastuzumab) were analyzed using three cross-linkers of different lengths: bis(sulfosuccinimidyl) suberate (BS3), bis(sulfosuccinimidyl) glutarate (BS2G), and 1,1'-carbonyldiimidazole (CDI). These findings demonstrate that FR-targeted XL-MS provides a strategy for identifying epitopes within patient-derived IC-antigens through the use of conserved antibody FRs. This approach may contribute to understanding antigen recognition mechanisms in autoimmune diseases and support the discovery of disease-relevant therapeutic targets."

Journal • Hepatology • Immunology • Oncology • Primary Biliary Cholangitis • HER-2 • TNFA

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events (clinicaltrials.gov) - P4 | N=32 | Completed | Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

STARTER: FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial (clinicaltrials.gov) - P4 | N=240 | Not yet recruiting | Sponsor: University Hospital, Clermont-Ferrand | Initiation date: Jun 2026 ➔ Dec 2026

Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The Impact of Antifibrotic Therapy on Laboratory and Immunological Parameters in Sarcoidosis (ERS 2026) - "Since TNF-α inhibitor (infliximab) antifibrotic therapy directly modulates inflammatory mediators, its effects may also be reflected in α-Klotho and IL2RA levels in patients with sarcoidosis... TNF-α inhibitor therapy did not substantially affect routine laboratory and pulmonary function parameters; however, higher α-Klotho and increased IL2RA levels may indicate an immunomodulatory effect. These proteins may serve as potential biomarkers for future sarcoidosis treatment."

Cardiovascular • Hematological Disorders • Immunology • Inflammation • Sarcoidosis • FGF23 • IL2RA

Disparity between eligibility and access to infliximab in pulmonary sarcoidosis at a UK tertiary Interstitial Lung Disease service (ERS 2026) - "Eligible n=16 Ineligible n=352 P value Age diagnosis 42 (±2.57) 48 (±0.67) 0.08 Male 12 (75%) 195 (55%) 0.12 Caucasian 14 (88%) 274 (78%) 0.36 Baseline DLCO diagnosis (mmol/min/kPa) (mean ±SEM) 6.1 (±0.78) 7.6 (±0.08) 0.36 Treatment at diagnosis 13 (81%) 145 (41%) <0.01** Fibrosis at review 10 (63%) 94 (27%) <0.01** Steroid duration (days) (mean ±SEM) 4184 (±959) 2119 (±154) <0.001*** Cumulative prednisolone (mg) (mean ±SEM) 45068 (±11581) 17518 (±1354) <0.001*** ≥2 DMARDS 5 (31%) 17 (5%) <0.001*** Conclusions Approximately 1 in 25 of our pulmonary sarcoidosis cohort met eligibility criteria for infliximab, with more advanced disease radiologically and higher treatment burden. Service development and commissioning pathways are required to ensure equitable access to infliximab for refractory disease."

Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • TNFA

A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis (clinicaltrials.gov) - P=N/A | N=100 | Active, not recruiting | Sponsor: Helwan University | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Oct 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2027

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Assessing the effectiveness of biologics in biologic-naïve patients with isolated small bowel Crohn's disease by double-balloon endoscopy. (PubMed, Expert Opin Biol Ther) - "This single‑center retrospective study included biologic‑naïve isolated SB‑CD patients who initiated infliximab (IFX) or ustekinumab (UST) between 2020 and 2025. Among biologic-naïve patients with isolated SB-CD, the overall ER rate after biologic treatment was 35.5%. IFX and UST showed comparable effectiveness in achieving ER."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease

Real-World Safety and Effectiveness of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis: A Post-Marketing Surveillance Study in Korea. (PubMed, Ocul Immunol Inflamm) - "One patient received prior infliximab; within the previous 3 months, 75.4% and 93.3% of patients received glucocorticoids and immunosuppressants, respectively. Regarding effectiveness, from baseline to 22 weeks, anterior chamber inflammation and vitreous haze tended to improve significantly; there was no BCVA worsening. In the real-world setting, adalimumab treatment showed an acceptable safety profile, with serious AEs reported in three patients but no serious ADRs related to adalimumab, and demonstrated potential effectiveness in Korean patients with NIIPPU."

Journal • P4 data • Real-world evidence • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Ulcerative Rectosigmoid Langerhans Cell Histiocytosis Mimicking Late-Onset Inflammatory Bowel Disease (ACG 2026) - "She had a history of indeterminate colitis diagnosed in 2023 with patchy colonic and small bowel involvement requiring multiple targeted immune modulating (TIM) therapies including vedolizumab, Risankizumab, infliximab, adalimumab, and azathioprine...On admission, she was found to have a Clostridium difficile infection and was started on fidaxomicin with clinical response...The patient was re-started on targeted LCH therapy with dabrafenib by hematology and nutritional support via total parenteral nutrition...B: On higher magnification, the lamina propria contains patchy histiocytic infiltrates, which are accompanied by scattered eosinophils and are in close association with colonic crypts with crypt injury, cryptitis and crypt abscesses (hematoxylin-eosin stains at 200x). C: CD1a immunohistochemistry is strongly and diffusely positive in the histiocytic infiltrates, supporting the diagnosis of Langerhans cell histiocytosis (CD1a stain, 200x)."

CNS Disorders • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Langerhans Cell Histiocytosis • CD1a

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants. (PubMed, World J Clin Pediatr) - "Variants in the TNFRSF1A gene may cause a wide range of clinical symptoms, including eye and intestinal lesions that are not typical of sJIA. All patients with fever and unusual sJIA symptoms should have molecular genetic testing for TNFRSF1A variants to confirm or exclude AID early. Early diagnosis enables timely therapy and prevents complications. Tocilizumab (39.3%), canakinumab (33.3%), and TNF inhibitors (21.2%) achieved remission in children with TNFRSF1A variants. Some patients required multiple bDMARD switches to achieve remission, highlighting the complexity of treatment decisions in this group."

Journal • Amyloidosis • CNS Disorders • Gastrointestinal Disorder • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammation • Oncology • Otorhinolaryngology • Pain • Pediatrics • Rheumatology • Ventriculomegaly • TNFRSF1A

From Gastrointestinal Graft-vs-Host Disease to Crohn Disease and Back Again: A Diagnostic Challenge in Post-Transplant Colitis (ACG 2026) - "Symptoms significantly improved with prednisone, vedolizumab, and ruxolitinib...He was treated with budesonide, upadacitinib, vedolizumab, infliximab, AAT, and thymoglobulin to target CD and GI GVHD...Further studies are needed to better characterize the relationship between post-transplant immune dysregulation and de novo IBD. Figure: March 2025 colonoscopy demonstrating Crohnâs Disease with active chronic ileocolitis with granulomas Figure: January 2026 colonoscopy demonstrating GI GVHD with focal ulcer and acute inflammation with increased apoptosis and focal loss of crypt"

Post-transplantation • Crohn's disease • Essential Thrombocythemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Myelofibrosis • Thrombocytosis • Transplantation

Colonic Metastases from Lung Adenocarcinoma Detected During an Evaluation of Recurrent Diarrhea Associated with Immune-Related Colitis. (PubMed, Intern Med) - "A 74-year-old man with advanced lung adenocarcinoma developed grade 3 diarrhea after treatment with pembrolizumab. Repeat colonoscopy before infliximab administration revealed multiple colonic metastases from lung adenocarcinoma. Gastrointestinal metastases should be considered in patients with atypical clinical or radiological findings, and repeated endoscopic evaluations may be useful before escalating immunosuppressive therapy."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Medically Refractory Acute Severe Ulcerative Colitis Complicated by Cytomegalovirus Managed With Diverting Loop Ileostomy During Pregnancy: A Case Report (ACG 2026) - "Case Description/ A 23-year-old woman with a 10-year history of ulcerative pancolitis being treated with upadacitinib 45mg and prednisone 40mg was transferred from another hospital at 25 weeks gestation with 2 weeks of bloody diarrhea. She had loss of response or non-response to adalimumab, vedolizumab, ustekinumab, and prior response to infliximab induction but lost response after switching to subcutaneous maintenance...Intravenous solumedrol was started on day 1 and upadacitinib was continued...She continued infliximab and valganciclovir and tapered off prednisone outpatient...Secondly, the management of CMV colitis during pregnancy may differ from non-pregnant individuals, as ganciclovir is typically avoided due to potential risks to the fetus...Figure: Figure 1: Representative image from flexible sigmoidoscopy showing severe colitis with erythema and ulcerations. Figure: Figure 2: Picture of the patientâs ostomy wound two weeks post-op."

Case report • Clinical • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

A case of refractory immune checkpoint inhibitor-induced colitis successfully treated with mirikizumab. (PubMed, Clin J Gastroenterol) - "Mirikizumab may be a promising therapeutic option for refractory ICIC, particularly in patients resistant to multiple biological agents."

Checkpoint inhibition • Journal • Breast Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology • Solid Tumor • Triple Negative Breast Cancer

Looking Beyond Clostridioides Difficile: Persistent Diarrhea Unmasking PembrolizumabâInduced ImmuneâMediated Colitis (ACG 2026) - "She continued to have 5â7 loose bowel movements daily and crampy abdominal pain despite oral vancomycin and a switch to fidaxomicin after 5 days...Disease was refractory to corticosteroids and infliximab but ultimately responded to upadacitinib...Figure: Figure 2. Gross bloody diarrheal stool and representative colonoscopic images from the ascending, descending, and sigmoid colon demonstrating diffuse erythema, friability, and ulceration, consistent with severe pancolitis due to immuneâmediated colitis in the setting of pembrolizumab therapy."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Lung Cancer • Solid Tumor

Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review. (PubMed, Front Pharmacol) - "TNF inhibitors (adalimumab, infliximab, etanercept, golimumab, certolizumab pegol) typically achieve Assessment of Spondyloarthritis International Society 40% improvement (ASAS40) rates of 40%-58% at 12-24 weeks versus 13%-24% with placebo, and maintain clinical benefit in many patients over 5-8 years. IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, brodalumab, netakimab) yield broadly similar ASAS40 responses (30%-50% versus 10%-20% placebo) and are particularly useful in patients with concomitant psoriasis with substantially reduced risk of tuberculosis reactivation. JAK inhibitors (tofacitinib, upadacitinib) represent the newest class, offering oral administration with ASAS40 responses of 40%-52% versus 13%-26% for placebo in both biologic-naïve and biologic-experienced AS, though cardiovascular safety considerations necessitate careful patient selection. Therapeutic selection should consider comorbidities (uveitis favors TNF monoclonal antibodies;..."

Journal • Review • Ankylosing Spondylitis • Back Pain • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Musculoskeletal Pain • Ocular Inflammation • Oncology • Ophthalmology • Pain • Psoriasis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Tuberculosis • Uveitis • IL17A

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Refractory Dasatinib-Induced Pancolitis: A Case of Dual Biologic Failure (ACG 2026) - "Infectious workup revealed enteropathogenic E. coli, treated with azithromycin without resolution...Repeat colonoscopy demonstrated severe pancolitis (left-predominant) with normal terminal ileum; pathology showed active focal colitis with rare cytomegalovirus (CMV) inclusions, treated with valganciclovir...Notably, this colitis proved exceptionally refractory, failing anti-integrin (vedolizumab) and escalated anti-TNF (infliximab) therapies before responding to anti-IL-23 inhibition (risankizumab-rzaa). Clinicians should maintain high suspicion for TKI-induced colitis in CML patients with chronic diarrhea, as early drug cessation and biologic rotation may be necessary for recovery. Figure: Serial colonoscopy images demonstrating severe, left-predominant dasatinib-induced pancolitis."

Clinical • Chronic Myeloid Leukemia • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Bowel Disease • Leukemia • ABL1 • BCR • IL23A